Clinical trial
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
NCT00821977 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
- Lead sponsor
- Novartis
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- November 30, 2008
- Completion date
- October 31, 2010
- Enrollment
- 338 (actual)
- Sites
- 176
Conditions
As the registry lists them; a condition with its own page is linked.